Private Equity
Andrea Alms Video: Money In Motion 121 - RNA Medicine Market
September 2024 - Private Equity
TRANSCRIPT:
Hello, my name is Andrea Alms. I'm a technology investor and financial manager and this is your money in motion. RNA therapeutics are a new class of medicines based on ribose nucleotide acids. Research has been ongoing for clinical use since the 1990s, with significant success in cancer in the early 20 tens. In 2020 and 2021, mRNA vaccines have been used to develop and combat coronavirus.
An example of RNA therapies include Mac Eugen. It is the only FDA approved RNA drug for age related macular degeneration. At Research and Markets, the global RNA based therapeutics market was estimated at 13.83 billion in 2023 and is expected to reach 25.47 billion by 2034, at a combat average growth rate of 5.71%. At markets and market, the market was 13.7 billion in 2023 and expected to reach 18 billion by 2028, at a growth rate of 5.6%.
At markets that U.S., the market was 9.57 billion in 2022 and expected to be 34.37 billion by 2032, at a 14% growth rate. Averaging the averages, the market size is 12.4 billion at a 8.4 growth rate. Thank you. This is your money, Your money in motion.